info@seagull-health.com
SeagullHealth
search
Adagrasib(Krazati)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Krazati(Adagrasib) Instructions:Uses,Dosage, Side Effects
Adagrasib, branded as KRAZATI, is an oral medication that targets KRAS G12C mutations, offering a targeted therapy option for patients with KRAS G12C-mutated non-small cell lung cancer and colorectal cancer. The drug works by irreversibly inhibiting the mutated KRAS protein, blocking its abnormal signaling pathway, and inhibiting tumor growth.
It is used both as a single agent for NSCLC and in combination with cetuximab for the treatment of CRC. It has shown promising results in clinical trials, providing a treatment option for patients with limited alternatives due to previous systemic therapies.
KRAZATI (adagrasib) is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that harbor the KRAS G12C mutation. This includes patients who have received at least one prior systemic therapy.
The recommended dose of KRAZATI is 600 mg orally once daily.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- haiousales@gmail.com
